AR018772A1 - Composicion farmaceutica para prevenir o tratar depresion, inquietud, enfermedad maniaca depresiva o psicopatia, compuesto heterociclico comprendido en lamisma, prodroga obtenida a partir del anterior, metodo para producir dicho compuesto y su uso - Google Patents

Composicion farmaceutica para prevenir o tratar depresion, inquietud, enfermedad maniaca depresiva o psicopatia, compuesto heterociclico comprendido en lamisma, prodroga obtenida a partir del anterior, metodo para producir dicho compuesto y su uso

Info

Publication number
AR018772A1
AR018772A1 ARP990101177A ARP990101177A AR018772A1 AR 018772 A1 AR018772 A1 AR 018772A1 AR P990101177 A ARP990101177 A AR P990101177A AR P990101177 A ARP990101177 A AR P990101177A AR 018772 A1 AR018772 A1 AR 018772A1
Authority
AR
Argentina
Prior art keywords
ring
group
pharmaceutical composition
optionally substituted
formula
Prior art date
Application number
ARP990101177A
Other languages
English (en)
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AR018772A1 publication Critical patent/AR018772A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Una composicion farmacéutica para prevenir o tratar depresion, inquietud, enfermedad maníaca depresiva o psicopatía que comprende un compuestoheterocíclico representado por la formula (I), en donde el anillo M es un anillo heterocíclico en donde -X =Y < es uno de -N=C<, -CO-N< o -CS-N<,Ra y Rb están enlazados el uno al otro para formar anillo A o éstos son iguales o diferentes y representan, independientemente, un átomo de hidrogenoo un sustituyente sobre el anillo M; el anillo A y el anillo Brepresenta, independientemente, un anillo homocíclico o heterocíclico opcionalmentesustituido, con la condicion que por lo menos uno de los dos es un anillo heterocícliclo opcionalmente sustituido; el anillo C es un anillo homocíclicoo heterocíclicoopcionalmente sustituido; el anillo Z es un anillo heterocíclico conteniendo nitrogeno opcionalmente sustituido; y n es un entero devalor 1 a 6, o una sal del mismo, que posee una accion antagonica al receptor de taquiquinina. Un compuesto heterocíclico representado por la formula (II),en donde R1 es un grupo alquilo C1-6; R2 es un grupo alcoxilo C1-6, grupo alquilo C1-6 opcionalmente halogenado, un átomo de halogeno, un grupohidroxilo o un grupo aralquiloxilo C7-15; X son 1 a 5 grupos seleccionados del grupo que consiste de un átomo de hidrogeno, un grupo alquilo C1-6 y unátomo de halogeno, con la condicion que (1) R1 es un grupo metilo y R2 es grupo trifluorometilo; X es un átomo de halogeno y (2) cuando R1 es ungrupo metilo y R2 es un grupo metoxilo; X es un átomo de hidrogeno o un átomo de halogeno o una sal del mismo. Una prodroga que se realiza con uncompuesto de acuerdo con el descripto. Un método para producir dicho compuesto por ciclacion de un compuesto de formula (III), en donde D y E representanlos grupos desde los cuales un grupo representado por la formula (IV) se forman junto con el átomo de nitrogeno adyacente a E; L representa un grupode comienzo y los otros símbolos poseen los mismos significados anteriormente descriptos, o una sal del mismo. Una composicion farmacéutica para prevenir
ARP990101177A 1998-03-19 1999-03-18 Composicion farmaceutica para prevenir o tratar depresion, inquietud, enfermedad maniaca depresiva o psicopatia, compuesto heterociclico comprendido en lamisma, prodroga obtenida a partir del anterior, metodo para producir dicho compuesto y su uso AR018772A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6999998 1998-03-19

Publications (1)

Publication Number Publication Date
AR018772A1 true AR018772A1 (es) 2001-12-12

Family

ID=13418890

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101177A AR018772A1 (es) 1998-03-19 1999-03-18 Composicion farmaceutica para prevenir o tratar depresion, inquietud, enfermedad maniaca depresiva o psicopatia, compuesto heterociclico comprendido en lamisma, prodroga obtenida a partir del anterior, metodo para producir dicho compuesto y su uso

Country Status (12)

Country Link
EP (2) EP1061926A2 (es)
KR (1) KR20010041991A (es)
CN (1) CN1291099A (es)
AR (1) AR018772A1 (es)
AU (1) AU751114B2 (es)
BR (1) BR9908895A (es)
CA (1) CA2321155A1 (es)
HU (1) HUP0100934A3 (es)
ID (1) ID25818A (es)
IL (1) IL136950A0 (es)
NO (1) NO20004144L (es)
WO (1) WO1999047132A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI287003B (en) 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
CA2423364A1 (en) * 2000-09-26 2003-03-25 Takeda Chemical Industries, Ltd. Preventives/remedies for emotional disorders
EP1591120A4 (en) * 2003-01-28 2009-06-10 Takeda Chemical Industries Ltd RECEPTOR AGONISTS
US20110136788A1 (en) 2008-08-07 2011-06-09 Minoru Maruyama Therapeutic agent for irritable bowel syndrome
SG11201606080SA (en) 2014-02-03 2016-08-30 Vitae Pharmaceuticals Inc Dihydropyrrolopyridine inhibitors of ror-gamma
HUE042335T2 (hu) 2014-10-14 2019-06-28 Vitae Pharmaceuticals Inc ROR-gamma dihidropirrolopiridin inhibitorai
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
EP3331876B1 (en) 2015-08-05 2020-10-07 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
EP3377482B1 (en) 2015-11-20 2021-05-12 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
MX2020000887A (es) 2017-07-24 2020-07-22 Vitae Pharmaceuticals Llc Inhibidores de ror?.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100214905B1 (ko) * 1991-05-31 1999-08-02 디. 제이. 우드, 스피겔 알렌 제이 퀴누클리딘 유도체
ATE242243T1 (de) * 1995-03-24 2003-06-15 Takeda Chemical Industries Ltd Zyklische verbindungen, ihre herstellung und ihre verwendung als tachykininrezeptorantagonisten

Also Published As

Publication number Publication date
HUP0100934A2 (hu) 2001-09-28
KR20010041991A (ko) 2001-05-25
NO20004144D0 (no) 2000-08-18
EP1184036A2 (en) 2002-03-06
WO1999047132A3 (en) 1999-11-11
CA2321155A1 (en) 1999-09-23
NO20004144L (no) 2000-10-10
WO1999047132A2 (en) 1999-09-23
CN1291099A (zh) 2001-04-11
EP1061926A2 (en) 2000-12-27
AU2853299A (en) 1999-10-11
IL136950A0 (en) 2001-06-14
BR9908895A (pt) 2000-12-05
ID25818A (id) 2000-11-09
AU751114B2 (en) 2002-08-08
HUP0100934A3 (en) 2002-09-30

Similar Documents

Publication Publication Date Title
AR018772A1 (es) Composicion farmaceutica para prevenir o tratar depresion, inquietud, enfermedad maniaca depresiva o psicopatia, compuesto heterociclico comprendido en lamisma, prodroga obtenida a partir del anterior, metodo para producir dicho compuesto y su uso
RU2495873C2 (ru) Новое урациловое соединение или его соль, обладающие ингибирующей активностью относительно дезоксиуридинтрифосфатазы человека
ATE334973T1 (de) Chinazolinverbindungen
NO20004624L (no) Benzensulfonamid-derivater og deres anvendelse som medikamenter
SE8501452L (sv) Nya 4-aroylimidazol-2-oner
BR0213646A (pt) Método, compostos e composição para controle de pragas invertebradas
AR030203A1 (es) Derivados de carbamato de 2-(s)-hidroximutilina, composiciones farmaceuticas que los comprenden, procedimiento para prepararlos y 2(s), 11-dihidroxi protegida-mutilina como compuesto intermediario
AR019167A1 (es) Derivados heteroaromaticos de piperazinas di-n-sustituidas y piperidinas 1,4-disustituidas, composiciones farmaceuticas y el uso de los mismos para lapreparacion de medicamentos
FI906108A0 (fi) Serotoninantagonister, deras framstaellning och dessa innehaollande laekemedel.
DK0992509T3 (da) Nye makrolid-derivater
FI940229A (fi) Trisykliset kondensoituneet heterosykliset yhdisteet, niiden valmistus ja käyttö
EA200100090A2 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
FR2804958B1 (fr) Derives de xanthine, leur procede de preparation et les intermediaires de ce procede, leur application comme medicament et les compositions pharmaceutiques les renfermant
AR012883A1 (es) Compuestos derivados de ciclobutilamina sustituida, composicion farmaceutica y agente antibacteriano.
ES500810A0 (es) Procedimiento de preparacion de aminoalcoxipirazoles
NO862494D0 (no) Fremgangsmaate for fremstilling av nye aromatiske forbindelser.
DE69620175T2 (de) Hydroxylamin-derivate mit anti-ischämischer wirkung und pharmazeutische zusammensetzungen diese enthaltend
ATE92058T1 (de) Pyrimidin-derivate, 2-(4-(alpha-heteroaryl-alphaaryl-(alpha-alkyl)-methoxy)-butyl)-1-piperaziny &gt; mit serotoninergischer wirkung.
NO20045540L (no) Nye 3-(4-okso-4H-kromen-2-yl)-(1H)-kinolin-4-on-forbindelser, en fremgangsmate for deres fremstilling og farmasoytisk sammensetninger inneholdende dem
ATE497497T1 (de) 1,2,4-triazolderivat, verfahren zu dessenherstellung, und dieses enthaltende pharmazeutische zusammensetzung
KR910004632A (ko) 신규한 1-옥사-2-옥소-8-아자스피로[4,5]데칸 유도체와 그들을 포함하는 약제학적 조성물 및 그 제조방법
BR0201312A (pt) Compostos de pirimidin-4-ona, processo para sua preparação e composições farmacêuticas contendo os referidos
KR960706492A (ko) 3-치환 1-아릴인돌 화합물 (3-substituted 1-arylindole compounds)
ATE5724T1 (de) Guanidinverbindungen, verfahren zu deren herstellung und diese enthaltende zusammensetzungen.
OA08436A (fr) Dérivé de l&#39;imino-3 pyridazine, procédé d&#39;obtention et compositions pharmaceutiques en contenant.